Zhang YW - Search Results

1

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.

Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, Santell L, Zhang YW, Su Y, Kaufman DW, Billeci KL, Mai E, Moffat B, Lim A, Duenas ET, Phillips HS, Xiang H, Young JC, Vande Woude GF, Dennis MS, Reilly DE, Schwall RH, Starovasnik MA, Lazarus RA, Yansura DG. Merchant M, et al. Among authors: zhang yw. Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. doi: 10.1073/pnas.1302725110. Epub 2013 Jul 23. Proc Natl Acad Sci U S A. 2013. PMID: 23882082 Free PMC article.

2

HGF/SF-met signaling in the control of branching morphogenesis and invasion.

Zhang YW, Vande Woude GF. Zhang YW, et al. J Cell Biochem. 2003 Feb 1;88(2):408-17. doi: 10.1002/jcb.10358. J Cell Biochem. 2003. PMID: 12520544 Review.

3

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

Zhang YW, Su Y, Volpert OV, Vande Woude GF. Zhang YW, et al. Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23. doi: 10.1073/pnas.2135113100. Epub 2003 Oct 10. Proc Natl Acad Sci U S A. 2003. PMID: 14555767 Free PMC article.

4

Met decoys: will cancer take the bait?

Zhang YW, Graveel C, Shinomiya N, Vande Woude GF. Zhang YW, et al. Cancer Cell. 2004 Jul;6(1):5-6. doi: 10.1016/j.ccr.2004.07.003. Cancer Cell. 2004. PMID: 15261136 Free article.

5

RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival.

Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. Shinomiya N, et al. Among authors: zhang yw. Cancer Res. 2004 Nov 1;64(21):7962-70. doi: 10.1158/0008-5472.CAN-04-1043. Cancer Res. 2004. PMID: 15520203

6

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.

Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, Furge K, Sun J, Rex K, Osgood T, Coxon A, Burgess TL, Vande Woude GF. Gao CF, et al. Among authors: zhang yw. Mol Cancer Ther. 2009 Oct;8(10):2803-10. doi: 10.1158/1535-7163.MCT-09-0125. Mol Cancer Ther. 2009. PMID: 19825800

7

Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis.

Zhang YW, Wang LM, Jove R, Vande Woude GF. Zhang YW, et al. Oncogene. 2002 Jan 10;21(2):217-26. doi: 10.1038/sj.onc.1205004. Oncogene. 2002. PMID: 11803465

8

Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor.

Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF. Zhang YW, et al. Oncogene. 2005 Jan 6;24(1):101-6. doi: 10.1038/sj.onc.1208181. Oncogene. 2005. PMID: 15531925

9

Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease.

Zhang YW, Su Y, Lanning N, Swiatek PJ, Bronson RT, Sigler R, Martin RW, Vande Woude GF. Zhang YW, et al. Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11740-5. doi: 10.1073/pnas.0505171102. Epub 2005 Aug 8. Proc Natl Acad Sci U S A. 2005. PMID: 16087873 Free PMC article.

10

Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation.

Staal B, Williams BO, Beier F, Vande Woude GF, Zhang YW. Staal B, et al. Among authors: zhang yw. Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2590-5. doi: 10.1073/pnas.1400744111. Epub 2014 Feb 3. Proc Natl Acad Sci U S A. 2014. PMID: 24550287 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,608 results

Search Page